Tissue factor plays a key role in determining plaque and blood thrombogenicity in atherothrombosis, making its specific inhibition a potential therapeutic target.
Tissue factor plays a key role in atherothrombosis and represents a promising therapeutic target for acute coronary syndromes.
Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular deaths. It is the leading cause of morbidity and mortality in the industrialized world. Plaque composition, rather than luminal stenosis, is recognized as the major determinant of this disease. Since tissue factor is found within atheroma and also in the bloodstream of atherosclerotic patients, it likely plays a key role in determining both plaque and blood thrombogenicity. Ongoing clinical and preclinical studies are evaluating the therapeutic possibilities of specific inhibition of the tissue factor pathway. Here, we will review the role of tissue factor in atherothrombosis and therapeutic applications.
Viles-González et al. (Wed,) conducted a review in Atherothrombosis. Tissue factor pathway inhibition was evaluated. Tissue factor plays a key role in determining plaque and blood thrombogenicity in atherothrombosis, making its specific inhibition a potential therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: